Jihui L. Hao

Tianjin Key Laboratory Of Digestive Cancer, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling.

Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: April 16, 2026

Risk factors and prognostic value of lymph node metastasis in patients undergoing curative resection for intrahepatic cholangiocarcinoma

Risk factors and prognostic value of lymph node metastasis in patients undergoing curative resection for intrahepatic cholangiocarcinoma

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: March 02, 2026

Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis.

Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis.

Journal: Signal transduction and targeted therapy

Published: January 03, 2026

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.

Journal: Nature communications

Published: August 28, 2025

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial.

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial.

Journal: Nature communications

Published: July 12, 2025

Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy.

Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy.

Journal: Communications biology

Published: July 10, 2025

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

Journal: Gut

Published: June 30, 2025

Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.

Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.

Journal: Hepatology international

Published: June 17, 2025

Corrigendum to "A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis" [Drug Resist. Updates 81 (2025) 101252].

Corrigendum to "A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis" [Drug Resist. Updates 81 (2025) 101252].

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: June 14, 2025

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.

Journal: Nature communications

Published: May 29, 2025

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Journal: Gut

Published: May 05, 2025

Correction to "Novel Indoleamine-2,3-dioxygenase-Targeted Pt(IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo".

Correction to "Novel Indoleamine-2,3-dioxygenase-Targeted Pt(IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo".

Journal: Journal of medicinal chemistry

Published: April 23, 2025

Showing 1-12 of 71

Last Updated: 09/26/2026